Interestingly, the neutralizing capacity of these autoantibodies inversely correlates with the onset of T1D in APECED patients with GAD65 autoantibodies, suggesting a potential protective role against T1D and possible therapeutic applications [141]. Here, GAD2 is linked to type 1 diabetes mellitus.